• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo

Gene Therapies and DNA Repair


  • Please log in to reply
105 replies to this topic

#31 Lazarus Long

  • Topic Starter
  • Life Member, Guardian
  • 8,116 posts
  • 242
  • Location:Northern, Western Hemisphere of Earth, Usually of late, New York

Posted 07 October 2003 - 01:22 PM

Here is a followup article in more depth from the New York times Science section today. It explains how epigenic expression is a factor during fetal development and how this can be as important as the actual genetic program the individual inherits and why environmental conditions and social factors for humans like economic status DOES significantly influence ultimate genetic expression.

Posted ImagePosted Image
http://www.nytimes.c...GENE.html?8hpib
A Pregnant Mother's Diet May Turn the Genes Around
By SANDRA BLAKESLEE
Published: October 7, 2003

With the help of some fat yellow mice, scientists have discovered exactly how a mother's diet can permanently alter the functioning of genes in her offspring without changing the genes themselves.

Posted Image
Duke University
Dietary supplements given to pregnant mice shift their offspring's coat color. These mice are genetically identical.


The unusual strain of mouse carries a kind of trigger near the gene that determines not only the color of its coat but also its predisposition to obesity, diabetes and cancer. When pregnant mice were fed extra vitamins and supplements, the supplements interacted with the trigger in the fetal mice and shut down the gene. As a result, obese yellow mothers gave birth to standard brown baby mice that grew up lean and healthy.

Scientists have long known that what pregnant mothers eat — whether they are mice, fruit flies or humans — can profoundly affect the susceptibility of their offspring to disease. But until now they have not understood why, said Dr. Randy Jirtle, a professor of radiation oncology at Duke and senior investigator of the study, which was reported in the Aug. 1 issue of Molecular and Cellular Biology.

The research is a milestone in the relatively new science of epigenetics, the study of how environmental factors like diet, stress and maternal nutrition can change gene function without altering the DNA sequence in any way.

Such factors have been shown to play a role in cancer, stroke, diabetes, schizophrenia, manic depression and other diseases as well as in shaping behavioral traits in offspring.

Most geneticists are focusing on sequences of genes in trying to understand which gene goes with which illness or behavior, said Dr. Thomas Insel, director of the National Institute of Mental Health. "But these epigenetic effects could turn out to be much more important. The field is revolutionary," he said, "and humbling."

Epigenetics may indeed hold answers to many mysteries that classical genetic approaches have been unable to solve, said Dr. Arturas Petronis, an associate professor of psychiatry at the Center for Addiction and Mental Health at the University of Toronto.

For example, why does one identical twin develop schizophrenia and not the other? Why do certain disease genes seem to affect or "penetrate" some people more than others? Why do complex diseases like autism turn up in more boys than girls?

For answers, epigeneticists are looking at biological mechanisms other than mutation that affect how genes function. One, called methylation, acts like a gas pedal or brake. It can turn gene expression up or down, on or off, depending on how much of it is around and what part of the genetic machinery it affects.

During methylation, a quartet of atoms called a methyl group attaches to a gene at a specific point and induces changes in the way the gene is expressed. The process often inactivates genes not needed by a cell. The genes on one of the two X chromosomes in each female cell are silenced by methylation.

Methyl groups and other small molecules may sometimes attach to certain spots on chromosomes, helping to relax tightly coiled strands of DNA so that genes can be expressed. Sometimes the coils are made tighter so that active genes are inactivated.

Methyl groups also inactivate remnants of past viral infections, called transposons. Forty percent of the human genome is made up of parasitic transposons.

Finally, methyl groups play a critical role in controlling genes involved in prenatal and postnatal development, including some 80 genes inherited from only one parent. Because these so-called imprinted genes must be methylated to function, they are vulnerable to diet and other environmental factors.

When a sperm and egg meet to form an embryo, each has a different pattern of methylated genes. The patterns are not passed on as genes are, but in a chemical battle of the sexes some of the egg and sperm patterns do seem to be inherited. In general, the egg seems to have the upper hand.

"We're compounds, mosaics of epigenetic patterns and gene sequences," said Dr. Arthur Beaudet, chairman of the molecular and human genetics department at Baylor College of Medicine in Houston. While DNA sequences are commonly compared to a text of written letters, he said, epigenetics is like the formatting in a word processing program.

Though the primary letters do not vary, the font can be large or small, Times Roman or Arial, italicized, bold, upper case, lower case, underlined or shadowed. They can be any color of the rainbow. Methylation is nature's way of allowing environmental factors to tweak gene expression without making permanent mutations, Dr. Jirtle said.

Fleeting exposure to anything that influences methylation patterns during development can change the animal or person for a lifetime. Methyl groups are entirely derived from the foods people eat. And the effect may be good or bad. Maternal diet during pregnancy is consequently very important, but in ways that are not yet fully understood.

For his experiment, Dr. Jirtle chose a mouse that happens to have a transposon right next to the gene that codes for coat color. The transposon induces the gene to overproduce a protein that turns the mice pure yellow or mottled yellow and brown. The protein also blocks a feeding control center in the brain. Yellow mice therefore overeat and tend to develop diabetes and cancer.

To see if extra methylation would affect the mice, the researchers fed the animals a rich supply of methyl groups in supplements of vitamin B12, folic acid, choline and betaine from sugar beets just before they got pregnant and through the time of weaning their pups. The methyl groups silenced the transposon, Dr. Jirtle said, which in turn affected the adjacent coat color gene. The babies, born a normal brownish color, had an inherited predisposition to obesity, diabetes and cancer negated by maternal diet.

Unfortunately the scientists do not know which nutrient or combination of nutrients silence the genes, but noted that it did not take much. The animals were fed only three times as much of the supplements as found in a normal diet.

"If you looked at the mouse as a black box, you could say that adding these methyl-rich supplements to our diets might reduce our risk of obesity and cancer," Dr. Jirtle said. But, he added, there is strong reason for caution.

The positions of transposons in the human genome are completely different from the mouse pattern. Good maps of transposons in the human genome need to be made, he said. For that reason, it may be time to reassess the way the American diet is fortified with supplements, said Dr. Rob Waterland, a research fellow in Dr. Jirtle's lab and an expert on nutrition and epigenetics.

More than a decade ago, for example, epidemiological studies showed that some women who ate diets low in folic acid ran a higher risk of having babies with abnormalities in the spinal cord and brain, called neural tube defects.

To reduce this risk, folic acid was added to grains eaten by all Americans, and the incidence of neural tube defects fell substantially. But while there is no evidence that extra folic acid is harmful to the millions of people who eat fortified grains regularly, Dr. Waterland said, there is also no evidence that it is innocuous.

The worry is that excess folic acid may play a role in disorders like obesity or autism, which are on the rise, he said. Researchers are just beginning to study the question.

Epidemiological evidence shows that undernutrition and overnutrition in critical stages of development can lead to health problems in second and third generations, Dr. Waterland said.

A Dutch famine near the end of World War II led to an increased incidence of schizophrenia in adults who had been food-deprived during the first trimester of their mothers' pregnancy. Malnourishment among pregnant women in the South during the Civil War and the Depression has been proposed as an explanation for the high incidence of stroke among subsequent generations.

And the modern American diet, so full of fats and sugars, could be exerting epigenetic effects on future generations, positive or negative. Abnormal methylation patterns are a hallmark of most cancers, including colon, lung, prostate and breast cancer, said Dr. Peter Laird, an associate professor of biochemistry and molecular biology at the University of Southern California School of Medicine.

The anticancer properties attributed to many foods can be linked to nutrients, he said, as well as to the distinct methylation patterns of people who eat those foods. A number of drugs that inhibit methylation are now being tested as cancer treatments. Psychiatrists are also getting interested in the role of epigenetic factors in diseases like schizophrenia, Dr. Petronis said.

Methylation that occurs after birth may also shape such behavioral traits as fearfulness and confidence, said Dr. Michael Meaney, a professor of medicine and the director of the program for the study of behavior, genes and environment at McGill University in Montreal.

For reasons that are not well understood, methylation patterns are absent from very specific regions of the rat genome before birth. Twelve hours after rats are born, a new methylation pattern is formed. The mother rat then starts licking her pups. The first week is a critical period, Dr. Meaney said. Pups that are licked show decreased methylation patterns in an area of the brain that helps them handle stress. Faced with challenges later in life, they tend to be more confident and less fearful.

"We think licking affects a methylation enzyme that is ready and waiting for mother to start licking," Dr. Meaney said. In perilous times, mothers may be able to set the stress reactivity of their offspring by licking less. When there are fewer dangers around, the mothers may lick more.

Posted Image

#32 kevin

  • Member, Guardian
  • 2,779 posts
  • 822

Posted 08 October 2003 - 10:04 PM

Evolution may just get a little boost from epigenetic control..

Click HERE to rent this GENETICS advertising spot to support LongeCity (this will replace the google ad above).

#33 kevin

  • Member, Guardian
  • 2,779 posts
  • 822

Posted 08 October 2003 - 10:11 PM

Link: http://www.eurekaler...u-tgo100803.php
Date: 10-08-03
Author: Christine Zeindler
Source: McGill University
Title: The genetics of blindness


Public release date: 8-Oct-2003
Contact: Christine Zeindler
christine.zeindler@muhc.mcgill.ca
514-934-1934
McGill University

The genetics of blindness
Treatment for the most common inherited cause of blindness, retinitis pigmentosa, is one step closer, according to investigators at the Research Institute of the McGill University Health Centre (MUHC). They are the first to link two new gene mutations in two French-Canadian families to loss of vision in humans. Their findings are published in this month's issue of the American Journal of Ophthalmology. This project was funded by the Canadian Institutes of Health Research (CIHR), les Fonds de la recherche en santé du Québec (FRSQ) and the Canadian Foundation Fighting Blindness.

Approximately 1.5 million people worldwide are affected by retinitis pigmentosa, which at the moment has no cure. This disease causes vision loss by progressive degeneration and death of the cells that make up the retina, the portion of the eye that responds to light.

"Retinitis pigmentosa is a devastating and complex disease," says principal investigator, Dr. Robert Koenekoop, director of pediatric ophthalmology at the Montreal Children's Hospital of the MUHC. "Many genes, gene mutations and symptoms are involved. The first steps to developing a treatment are the characterization of all these factors. Important progress has been made by identifying two important gene mutations present in the French-Canadian population."

Koenekoop in collaboration with MUHC geneticist, Dr. Guy Rouleau, examined two very large French-Canadian families afflicted with retinitis pigmentosa for four generations. Ophthalmic evaluations and genetic analysis were used to characterize the gene mutations and the resulting phenotype. They demonstrated that these mutations resulted in variable, severe forms of the disease and in some cases other neurological disorders, such as hearing loss.

"Our findings show that different gene mutations result in different symptoms of the disease," says Rouleau. "Our study will provide hope to those families who have suffered from this disease for generations and will lead to new screening and diagnostic tests."


"We were fortunate to have the facilities and expertise to make this discovery," concludes Koenekoop. "This project was an excellent example of genetic and ophthalmic cross-disciplinary research." About the Research Institute of the McGill University Health Centre The Research Institute of the McGill University Health Centre (MUHC), located in Montreal, Quebec, is Canada's largest concentration of biomedical and health-care researchers. The institute has over 500 researchers, nearly 650 graduate and post-doctoral students and 306 laboratories devoted to research. The mission of the institute is to facilitate investigator-initiated and discovery-driven research that creates new knowledge. This research is inextricably linked to clinical programs, which provide a bench-to-bedside-to-community continuum. The MUHC research institute is renowned as a world-class research institution that operates at the forefront of new knowledge, innovation, trends, and technologies.


###

About the Canadian Institutes of Health Research
CIHR is Canada's premier agency for health research. Its objective is to excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health for Canadians, more effective health services and products, and a strengthened health care system.

#34 kevin

  • Member, Guardian
  • 2,779 posts
  • 822

Posted 15 October 2003 - 03:07 PM

Link: http://www.eurekaler...b-rfg101303.php
Date: 10-14-03
Author: Jonnie Rohrer
Source: Wake Forest University
Title: Researchers find genetic link to prostate cancer


Public release date: 14-Oct-2003
Contact: Jonnie Rohrer
jrohrer@wfubmc.edu
336-716-6972
Wake Forest University Baptist Medical Center


Researchers find genetic link to prostate cancer
WINSTON-SALEM, N.C. – Some men may be more prone to prostate cancer because a variation in a specific gene makes them more susceptible to the harmful effects of cancer-causing agents, a new study shows. The results of the study led by Wake Forest University School of Medicine researcher Jianfeng Xu, Ph.D. will be published today in the British Journal of Cancer.

Xu and his team, in collaboration with researchers at Johns Hopkins University, looked at variations in a gene that controls the body's response to carcinogens in the environment as well as hormones natural to the body. They found men with prostate cancer often had a different version of the gene than men who were not affected by the disease.

Scientists believe their findings may hold important clues in understanding what environmental factors may trigger the development of prostate cancer.

"Previous research suggests prostate cancer arises in certain individuals due to a combination of genetic and environmental factors," said Xu. "Our study suggests that the genetic make-up of some men leaves them more susceptible to potential carcinogens in the environment or hormones in the body that could trigger the disease."

The researchers analyzed a gene called CYPIBI, which is thought to play an important role in the development of cancer.

CYPIBI normally plays a dual role in the body and therefore has been suggested to both cause and prevent cancer. It helps the body eliminate environmental chemicals that can cause cancer but also can activate some hormones, turning them into cancer-causing agents.

Tiny variations in the gene may alter its function, say the researchers, with some increasing the cancer-causing effects of the gene and others enhancing its ability to prevent cancer.

The team looked separately at 13 variations in CYPIBI and clusters of these variations, called polymorphisms, commonly found in Caucasian male populations. They found that one cluster of variations was more common in men with prostate cancer who had no family history of the disease, while another combination appeared more frequently in men who did not have the disease.

The study suggests men with a particular gene variant have an increased risk of prostate cancer. "It's an exciting finding because we know the gene interacts with certain cancer-causing chemicals," said Xu. "Studying this more closely will bring us closer to finding out what factors in the environment or within the body may trigger the disease."

This information will help scientists better understand how changes in the gene alter its dual functions in the body, and allow them to identify people at high risk and advise them on ways to prevent the disease.


###
Media Contacts: Jonnie Rohrer, 336-716-6972, Karen Richardson or Robert Conn, 336-716-4587.

#35 kevin

  • Member, Guardian
  • 2,779 posts
  • 822

Posted 15 October 2003 - 03:43 PM

Link: http://www.reuters.c...storyID=3613314
Date: 10-14-03
Author: staff
Source: Reuters
Title: Study Finds Gene Mutation Linked to Long Life
Comment: Nir Barzilai spoke on at the IABG on Cellular Nutrient Sensing and Longevity


Study Finds Gene Mutation Linked to Long Life
Tue October 14, 2003 04:58 PM ET
CHICAGO (Reuters) - A gene that affects the size of molecules in blood cholesterol may help people live to be 100 or older by protecting against heart disease, stroke, diabetes and other diseases, a study said on Tuesday.
The genetic propensity may be inherited, lending further proof to theories that living a long life may depend on inheriting the right genes, the researchers said.

The findings from the Albert Einstein College of Medicine, New York, were based on a look at long-lived Ashkenazi Jewish men and women and their children.

The Jews of Eastern European descent were chosen because centuries of social isolation led to a genetic similarity that allows for more precise research.

Among 213 older persons in the study, the average age was 98, and nearly half were over 100 years in age. The study also looked at 216 of their adult children.

The researchers found that the centenarians they studied were three times more likely than the general population to have a genetic mutation that alters an enzyme involved in regulating blood fats and their particle size, leading to larger particles.

Their offspring were more than twice as likely to have the same mutation.

Ashkenazi families with the mutation tended to have increased levels of high density lipoproteins -- HDL, or so-called "good," cholesterol -- which appears to provide a protection against heart disease. They also had larger molecules in HDL and in low density lipoprotein -- LDL, or so-called "bad," cholesterol.

The study, published in this week's Journal of the American Medical Association, said there is increasing evidence that people with small LDL particles are at increased risk for heart disease.

The Einstein researchers speculated that the larger particle size inhibits bad cholesterol from penetrating artery walls, where fats can build up as plaque.

"For this particular group of centenarians and their children, bigger lipoproteins do seem to be better," said Nir Barzilai, who led the research.

"Learning more about this trait, which appears to be highly heritable among these individuals, could do much to broaden our understanding of why they not only live extraordinarily long lives but also age remarkably well without developing many of the diseases typically associated with later life," he added.

#36 chubtoad

  • Life Member
  • 976 posts
  • 5
  • Location:Illinois

Posted 21 October 2003 - 10:46 PM

http://www.scienceda...31021063402.htm
Source: Johns Hopkins Medical Institutions
Date: 2003-10-21

Gene Silencer May Improve Chemo And Radiation


Like bacteria that resist common antibiotics, cancer cells can survive chemotherapy and radiation. Radiation oncologists at the Johns Hopkins Kimmel Cancer Center report they have found a gene "silencer" that blocks a cancer cell's ability to repair itself after drugs and radiation cause damage.

Engineered pieces of protein-encoding RNA (ribonucleic acid), the mirror image of genes' building blocks, were used to target repair proteins in cancer cells effectively shutting the RNA down. Unable to make the necessary repair proteins, cancer cells then become susceptible to the therapy.

"By dismantling the cancer cell's machinery to produce these repair proteins, we destroy its ability to withstand toxic chemotherapy and radiation treatments," says Theodore DeWeese, M.D., director of the Department of Radiation Oncology at the Johns Hopkins Kimmel Cancer Center.

The researchers saw a decrease in the production of targeted repair proteins by approximately 90 percent, and were able to reduce the amount of radiation needed to damage cells.



#37 kevin

  • Member, Guardian
  • 2,779 posts
  • 822

Posted 22 October 2003 - 04:43 AM

Researchers find two genes in mice which give rise to age related macular degeneration.
XREF: http://imminst.org/f...t=0

#38 kevin

  • Member, Guardian
  • 2,779 posts
  • 822

Posted 22 October 2003 - 04:48 AM

Link: http://www.bioresear...rrent Headlines
Date: 10-21-03
Author: -
Source: BioResearch Online
Title: Gene Controls Age at Onset of Alzheimer's and Parkinson's Diseases


Gene Controls Age at Onset of Alzheimer's and Parkinson's Diseases
10/21/2003 DURHAM, N.C. - By applying a new technique that combines independent lines of genomic evidence, Duke University Medical Center researchers and colleagues have identified a single gene that influences the age at which individuals first show symptoms of Alzheimer's and Parkinson's diseases.

Such genes that can impact patients' age at onset for the two very prevalent neurological disorders are of particular interest as alternative targets for treatment, said Margaret Pericak-Vance, Ph.D., director of the Duke Center for Human Genetics. Drugs that delay the onset of Alzheimer's or Parkinson's diseases beyond the normal human lifespan would effectively prevent them in patients at risk for the disorders, she added.

Alzheimer's disease is the most common cause of dementia among people over the age of 65, affecting up to 4 million Americans. Parkinson's disease -- characterized by tremors, stiffness of the limbs and trunk, slow movements and a lack of balance -- afflicts approximately 50,000 Americans each year. Both are complex disorders involving multiple genes.

"Although physicians generally consider Alzheimer and Parkinson diseases to be distinct disorders, the two exhibit a lot of overlap both clinically and pathophysiologically," said Jeffery Vance, M.D., director of Duke's Morris K. Udall Parkinson's Disease Research Center and associate director of the Duke Center for Human Genetics. "This study emphasizes the similarity between the two diseases by highlighting a single gene that influences their age of onset."

The team reports their findings in the Dec. 15, 2003, issue (available online Oct. 21) of Human Molecular Genetics and will present the work as a keynote paper at the annual meeting of the American Society of Human Genetics, which will be held Nov. 4-8, in Los Angeles. The major funding for the study was provided by the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, the Alzheimer's Association, the Institute de France, and the American Federation for Aging Research.

The team's earlier work identified a broad chromosomal region linked to the age at onset of Alzheimer's and Parkinson's diseases. The new research -- led by Pericak-Vance, Vance, John Gilbert, Ph.D. and Yi-Ju Li, Ph.D., of the Duke Center for Human Genetics and Jonathan Haines, Ph.D., of Vanderbilt University Medical Center -- narrows that region of the genome, which contained many hundreds of genes, to a single gene known as glutathione S-transferase omega-1 or GSTO1.

The researchers overlaid three independent lines of genetic evidence to reveal those genes more likely to play a role in the disorders' age at onset -- a method, called genomic convergence, which the Duke team developed.

The researchers first focused on Alzheimer's disease by comparing the activity of genes in the hippocampus -- a part of the brain affected by the disorder -- of unaffected individuals and Alzheimer's patients. The experiment uncovered four genes, including GSTO1, located in the region of the genome earlier linked to age at onset, the researchers report.

An additional analysis involving 1,773 patients with Alzheimer's disease and 635 patients with Parkinson's disease later found that of those four genes, only GSTO1 showed genetic differences associated with age at onset.

"By combining evidence based on gene expression and genetic association, we found a gene that modifies when the diseases start," said Li, the study's first author. "Understanding the role this gene plays in Alzheimer and Parkinson diseases may, in the future, lead to a means to delay the disorders' onset," she added, noting that even a short delay would benefit at-risk patients.

The Center for Human Genetics is one of five centers within Duke's Institute for Genome Sciences and Policy. The institute represents Duke University's comprehensive response to the broad challenges of the genomic revolution.

The international research team included scientists representing 17 institutions in the United States, the United Kingdom and Australia. Additional funding was provided by the Hilles Families Foundation, the U.S. Public Health Service, the California Department of Health Services, the Fran and Ray Stark Foundation Fund for Alzheimer's Disease Research and GlaxoSmithKline

#39 kevin

  • Member, Guardian
  • 2,779 posts
  • 822

Posted 24 October 2003 - 06:08 AM

Link: http://www.eurekaler...m-mgl102103.php
Date: 23-Oct-2003
Author: Constance Burr cburr@nih.gov 301-443-4536
Source: NIH/National Institute of Mental Health
Title: Mutant gene linked to obsessive compulsive disorder


Mutant gene linked to obsessive compulsive disorder
Analysis of DNA samples from patients with obsessive compulsive disorder (OCD) and related illnesses suggests that these neuropsychiatric disorders affecting mood and behavior are associated with an uncommon mutant, malfunctioning gene that leads to faulty transporter function and regulation. Norio Ozaki, M.D., Ph.D., and colleagues in the collaborative study explain their findings in the October 23 Molecular Psychiatry.

Researchers funded by the National Institutes of Health have found a mutation in the human serotonin transporter gene, hSERT, in unrelated families with OCD. A second variant in the same gene of some patients with this mutation suggests a genetic "double hit," resulting in greater biochemical effects and more severe symptoms. Among the 10 leading causes of disability worldwide, OCD is a mental illness characterized by repetitive unwanted thoughts and behaviors that impair daily life.

"In all of molecular medicine, there are few known instances where two variants within one gene have been found to alter the expression and regulation of the gene in a way that appears associated with symptoms of a disorder," said co-author Dennis Murphy, M.D., National Institute of Mental Health (NIMH) Laboratory of Clinical Science. "This step forward gives us a glimpse of the complications ahead in studying the genetic complexity of neuropsychiatric disorders."

Psychiatric interviews of the patients' families revealed that 6 of the 7 individuals with the mutation had OCD or OC personality disorder and some also had anorexia nervosa (AN), Asperger's syndrome (AS), social phobia, tic disorder, and alcohol or other substance abuse/dependence. Researchers found an unusual cluster of OCD, AN, and AS/autism, disorders together with the mutation in approximately one percent of individuals with OCD.

The scientists analyzed DNA from 170 unrelated individuals, including 30 patients each with OCD, eating disorders, and seasonal affective disorder, plus 80 healthy control subjects. They detected gene variants by scanning the hSERT gene's coding sequence. A substitution of Val425 for Ile425 in the sequence occurred in two patients with OCD and their families, but not in additional patients or controls. Although rare, with the I425V mutation found in two unrelated families, the researchers propose it is likely to exist in other families with OCD and related disorders.

In addition to the I425V mutation, the two original subjects and their two siblings had a particular form of another hSERT variant, two long alleles of the 5-HTTLPR polymorphism. This variant, associated with increased expression and function of the serotonin transporter, suggests a "double hit," or two changes within the same gene. The combination of these changes, both of which increase serotonin transport by themselves, may explain the unusual severity and treatment resistence of the illnesses in the subjects and their siblings.

"This is a new model for neuropsychiatric genetics, the concept of two or maybe more within-gene modifications being important in each affected individual. This is also probably the first report of a modification in a transporter gene resulting in a gain rather than a decrease in function," said NIMH Director Thomas Insel, M.D.

SERT allows neurons, platelets, and other cells to accumulate the chemical neurotransmitter serotonin, which affects emotions and drives. Neurons communicate by using chemical messages like serotonin between cells. The transporter protein, by recycling serotonin, regulates its concentration in a gap, or synapse, and thus its effects on a receiving neuron's receptor.

Transporters are important sites for agents that treat psychiatric disorders. Drugs that reduce the binding of serotonin to transporters (selective serotonin reuptake inhibitors, or SSRIs) treat mental disorders effectively. About half of patients with OCD are treated with SSRIs, but those with the hSERT gene defect do not seem to respond to them, according to the study.

Any vulnerability to OCD from gene effects most likely interacts with events in the environment like stresses, other factors like gender, and treatments, Murphy said. By examining the serotonin transporter gene's mutation and flawed regulation in individuals with OCD, the new research provides insights on transporter function and on the consequences of the variant, which may lead to tests to identify and treat mental illness.

A related study in the August 2003 Molecular Pharmacology tested consequences of the hSERT variant. The report is considered the first to identify a coding mutation in a transporter linked to a psychiatric condition. Researchers found that the I425V mutation of hSERT increased the transport activity of this protein, capturing more serotonin and most likely reducing effects at the receiving neuron's receptors, outperforming the common transporter. The mutant molecule was not regulated normally and did not respond to cell signals that activate the common form of the transporter. Gary Rudnick and Fusun Kilic, Yale University School of Medicine, with Murphy at NIMH, conducted this research, which was funded by the Rockefeller Brothers Fund, the National Alliance for Research on Schizophrenia and Depression, and the National Institute on Drug Abuse (NIDA).

Participants in the study published in Molecular Psychiatry were: Norio Ozaki, Fujita Health University School of Medicine, Toyoake, Aichi, Japan, whose early work on the project was supported by awards from the NIMH Intramural Programs of the National Institute of Alcohol Abuse and Alcoholism (NIAAA) and the NIMH; David Goldman, NIAAA; Walter Kaye and Katherine Plotnicov, University of Pittsburgh Medical Center and Western Psychiatric Institute and Clinic; Benjamin Greenberg, Butler Hospital and Brown University School of Medicine; Jaakko Lappalainen, Yale University School of Medicine; and Gary Rudnick, Department of Pharmacology, Yale University School of Medicine; Dennis Murphy, NIMH Laboratory of Clinical Science.


###
NIMH, NIDA, and NIAAA are part of the National Institutes of Health (NIH), the Federal Government's primary agency for biomedical and behavioral research. NIH is a component of the U.S. Department of Health and Human Services.

#40 kevin

  • Member, Guardian
  • 2,779 posts
  • 822

Posted 30 October 2003 - 10:02 PM

Link: http://newsroom.msu....623/content.htm
Date: 10-30-03
Author: -
Source: Michigan State University
Title: MSU team discovers gene mutations that cause hearing loss


MSU team discovers gene mutations that cause hearing loss
Contact: Jill Elfenbein, Audiology and Speech Sciences, (517) 353-7837, jillelf@msu.edu; Karen Friderici, Microbiology and Molecular Genetics, (517) 355-6463, Ext. 1558, frideric@msu.edu; Rachel Fisher, MSU Hearing Research Center, (517) 353-4946, fisher@msu.edu; or Tom Oswald, University Relations, (517) 355-2281, oswald@msu.edu

10/30/2003

EAST LANSING, Mich. – Michigan State University researchers have discovered a set of gene mutations that cause progressive hearing loss, a discovery that should provide significant clues in the hunt to solve the puzzle of acquired hearing loss.

The research, which was led by faculty from the MSU Hearing Research Center, will be published in the November issue of the American Journal of Human Genetics.

The gene involved, known as DFNA 20, is known to play an essential role in the structure of the inner ear, the cochlea. It’s one of nearly 100 genes known to play a role in hearing loss.

“Until now, no mutations had been discovered in this gene, so this finding is expected to provide new insights that will help researchers understand more about the biology of progressive loss,” said Rachel Fisher, director of the MSU Hearing Research Center and one of the project leaders. “One possibility is that the mutations interfere with processes that allow ears to repair damage done by noise or aging.”

As with any health threat, early detection is the key to proper care.

“Knowing what the gene is means that you can maybe move toward preventing hearing loss or, possibly, curing it,” said Karen Friderici, an MSU associate professor of microbiology and molecular genetics, whose laboratory identified the gene.

An estimated 28 million Americans, including one in three over the age of 60, have hearing loss. Unfortunately, very little is known about how the hearing mechanism ages.

This research began in Michigan about six years ago with members of a family who reported the onset of hearing-related communication problems as they neared the age of 30. The project eventually led Fisher and her colleagues to Cornwall, England, where, by looking through census data, they found that this family had hearing problems as far back as 1800.

These findings are already benefiting the families involved in the project, said Jill Elfenbein, an MSU associate professor of audiology and speech sciences and a team member.

“The grandmother in Michigan who initiated contact with MSU now has the satisfaction that we have identified the cause of the hearing loss that affects approximately half of her descendants,” she said. “For the youngest of her grandchildren, there is the potential that 20 years from now, when they will begin to feel the impact of the family hearing loss, we may know how to reduce the effect of the gene mutation.”
Initial identification of the gene was achieved at MSU. Additional mutations were found through collaborations with the University of Iowa and the Baylor College of Medicine. The National Institutes of Health also was a partner in the project.

Funding was provided by the MSU Foundation, the National Institute for Deafness and Other Communication Disorders, and the Pearl Aldrich Foundation.

[EDITORS NOTE: For copies of the published paper, please contact Tom Oswald, MSU University Relations, at (517) 355-2281. Due to issues of confidentiality, names of members of the families who made this research possible cannot be released. However, another good source on hearing loss issues is Ann Liming, national president of the Self Help for Hard of Hearing and a specialist in the State of Michigan’s Division on Deaf and Hard of Hearing. She can be contacted at (517) 334-9499 or liminga@michigan.gov.]

#41 chubtoad

  • Life Member
  • 976 posts
  • 5
  • Location:Illinois

Posted 31 October 2003 - 01:13 AM

http://www.scienceda...31030061801.htm
Source: Howard Hughes Medical Institute
Date: 2003-10-30


Gene-expression Atlas Will Provide New Direction For Brain And Spinal-cord Studies


Using a technique to insert fluorescently labeled genes into live mice, researchers have created a new atlas that will quite literally light the way for neuroscientists to explore the maze of connections between cells in the central nervous system (CNS).

The researchers who developed the atlas said it would enable scientists to determine when and where specific genes are switched on in the CNS. Researchers can use such clues to explore the molecular machinery that coordinates neural development and to chart the functional circuitry of the brain and spinal cord. All data from the Gene Expression Nervous System Atlas (GENSAT) BAC Transgenic Project, will be available online to researchers worldwide at http://www.gensat.org.


Data derived from the project could have a have major impact on the understanding of neurological disorders, according to the project's leaders, Howard Hughes Medical Institute (HHMI) investigator Nathaniel Heintz and Mary E. Hatten at The Rockefeller University. The researchers reported the first results from the project in an article published in the October 30, 2003, issue of the journal Nature. Heintz and Hatten collaborated with HHMI investigator Alexandra Joyner at the New York University School of Medicine, as well as with scientists from East Tennessee State University, Roswell Park Cancer Institute and the National Institute of Neurological Disorders and Stroke.

To track gene expression, the researchers developed bacterial artificial chromosomes (BACs) that contained a segment of a mouse chromosome representing a single gene found in the central nervous system -- including the regulatory segments that determine when and where it will be switched on and off. Instead of inserting only the mouse gene into the BAC, the researchers also spliced in a gene that expressed a green fluorescent protein.

When the researchers introduce the BACs into CNS cells, the cells emit a green fluorescence if the genes the BAC contains are switched on. In addition, since the natural, or endogenous, gene remains undisturbed, the labeled cells are otherwise normal and viable. The GENSAT BAC Transgenic Project will make available an atlas of micrographic images depicting the gene expression in the labeled cells, the "library" of BACs, and the transgenic mice that contain the BACS.

So far, Heintz, Hatten and their colleagues have applied the technique to gather data on some 400 genes expressed in the CNS and they expect the database to grow at a rate of several hundred genes per year.

"This project will give researchers an atlas of gene expression at a cellular resolution, which allows them to visualize and characterize novel cell populations and subpopulations that express a given gene," said Heintz. "This information will allow investigators to form very precise hypotheses about a gene's function based on from where and when it is expressed in the brain, which consists of thousands of types of cells."


The project is also unique because it will provide experimental materials for neuroscientists. "The library of BAC vectors that we are developing will enable them to identify and access any major cell type in the brain. And the transgenic mice themselves will give neuroscientists animals in which specific living cells of interest are fluorescently labeled, so that they can image, separate or electrophysiologically record from them," said Heintz. "This access to mice with precisely labeled cell populations will stimulate the whole area of neurobiology that studies cell physiology and connections," he said.

Joyner, who helped direct the group that produced the transgenic mice for the project, said, "those of us who study a particular area of the brain can use these mice to discover what genes are expressed in that area. We may well see new expression patterns -- in which different genes are expressed in different subsets of cells -- that tell us these areas are not as homogeneous as we believed. This tells is that there is some new biology going on that we didn't suspect. Thus, these mice will be an invaluable resource for further exploration."

In the Nature article, the researchers presented data on a variety of CNS genes to illustrate the utility of the atlas. The genes included those that code for "lineage markers" that reveal the location and development of specific subpopulations of CNS cells; guidance molecules that govern the wiring of neural circuitry during embryonic development; and molecules that enable researchers to trace the migration of neural cells during development of the brain and spinal cord.

Heintz and his colleagues also hope that data from the atlas will enable better functional analyses of neural circuitry by permitting researchers to manipulate individual circuits in the brain. "It's well known that the nervous system works by forming and using very specific circuits," said Heintz. "And, in some cases, those circuits have been mapped out in cellular detail, so that investigators know which neurons in the brain actually contribute to a circuit controlling a specific behavior. Although this is somewhat futuristic, several laboratories are working on genetic methods to control the electrical activity of neurons. The GENSAT project will enable these strategies to be targeted to specific cells in a circuit, to better understand how that circuit operates and controls behavior."

For researchers studying neurological disorders, the atlas will enable dissection of molecular mechanisms and neural circuitry underlying those disorders, said Heintz. "There are now many mouse models of neurodegenerative disease, such as Huntington's disease, that fairly accurately reproduce the symptoms seen in humans," he said. "Yet, in most cases, it's hard to know where the primary pathology lies -- which cells are responsible for contributing to the primary effects in the disease. Based on data provided by this atlas, investigators can express a mutant protein that causes a human disease in each of the cell types implicated in the disease, and find out which ones are primarily affected by this mutant gene product. Such studies will enable to dissect mechanisms of degeneration at a much more precise level in the intact brain."



#42 chubtoad

  • Life Member
  • 976 posts
  • 5
  • Location:Illinois

Posted 31 October 2003 - 08:39 PM

http://www.scienceda...31031064709.htm
Source: Stanford University
Date: 2003-10-31


Researchers Create 'Supersized' Molecule Of DNA


Scientists at Stanford University have created an expanded molecule of DNA with a double helix wider than any found in nature. Besides being more heat resistant than natural DNA, the new version glows in the dark - a property that could prove useful in detecting genetic defects in humans. A description of the molecule, dubbed ''xDNA,'' is published in the Oct. 31 issue of the journal Science.

''We've designed a genetic system that's completely new and unlike any living system on Earth,'' said Eric T. Kool, a professor of chemistry at Stanford and co-author of the Science study. ''Unlike natural DNA, our expanded molecule is fluorescent and is considerably more stable when subjected to higher temperatures.''
Natural bases

DNA typically comes in the form of a double helix - two parallel strands of genetic information coiled together like a long, twisted ladder. Each rung of the ladder consists of two complementary units, called ''bases,'' that bind together in ''base pairs.''

Only four bases exist in nature: adenine (A), thymine (T), guanine (G) and cytosine ©. Because of their unique size and shape, T always pairs with A, and G with C. Any other combination (such as A-C or G-T) would be too wide or too narrow to fit inside the double helix.

Human DNA consists of about three billion A-T and G-C base pairs arranged in a specific sequence that spells out all of the genetic instructions needed to build a healthy person. However, if just one or two base pairs end up in the wrong order, the genetic code could go haywire and result in a potentially devastating birth defect or a chronic disease, such as cancer or sickle cell anemia.

''The bases are where the real action occurs,'' Kool noted. ''What we've done in our experiment is to actually change them.''

xDNA

In their study, Kool and his co-workers followed up on earlier experiments by chemist Nelson Leonard, now at the California Institute of Technology. In the 1970s, Leonard inserted a ring of benzene into a molecule of A. The result was an expanded base - xA - that was about one-third wider than normal A.

The Stanford group used a similar technique to create xT - a synthetic base that's twice as big as natural T. The next challenge was to make these oversized bases fit snugly inside a double helix.

''We started from scratch,'' Kool recalled. ''We spent years, in fact, making these stretched molecules, and then years trying to see if they would form a helix.''
Success finally came when they paired an expanded A with a normal T (xA-T) and an expanded T with a normal A (xT-A). Using this arrangement, the researchers were able to synthesize a double helix that could stretch just enough to hold the expanded base pairs intact. The result was a stable new form of DNA that's about 20 percent wider than natural DNA. The researchers named the new molecule ''expanded DNA,'' or xDNA.

''Previously, scientists have worked on making new base pairs for the natural DNA helix,'' Kool explained. ''What we've done is come up with a whole new helix instead.'' The lab's next goal is to create expanded versions of the other two bases, G and C, he added.
Size matters

The research team also discovered several attributes of xDNA not found in natural DNA. For example, xDNA is much more thermally stable than natural DNA. In the lab, natural DNA fell apart at 71 F (21.3 C), while xDNA remained intact at 132 F (55.6 C).

''Almost everything bigger stacks better than things that are smaller, and base pairs are no exception,'' Kool said. ''They'd rather be stacked on one another, and that keeps the helix together and thus more stable. With DNA, size matters.''

Bigger molecules also tend to be fluorescent, he added, which probably explains why - unlike natural DNA - xDNA emits a violet light that's easy to see under a microscope.

''It's possible that every base pair in xDNA is fluorescent,'' Kool said. ''That means each base pair could change color or intensity when it finds a complementary strand of natural DNA or RNA.''

This fluorescent property could prove useful for medical biopsies, he said, adding: ''You need fast and accurate ways of genetically typing cells, and I think color is an interesting way of doing that. You'd put a thin slice of tissue on a slide, stain it with your molecule, look at it under a microscope and say, 'Ah! This tumor has this mutation in its DNA, so now we know what drugs to use to treat it.'''

Alien life

In nature, DNA carries all of the hereditary information that's passed on to the next generation. Is xDNA also capable of replicating? That's something Kool hopes to find out.

''This new DNA couldn't function in the natural system on Earth,'' he cautioned. ''It's too big. However, we like to think that one day it could be the genetic material for a new form of life, maybe here or on another planet. So when we send explorer robots to Jupiter's moon, Europa, and look under the ice, we'll have an idea about what sort of life we should be looking for.''


The Science study was co-written by Stanford graduate students Haibo Liu (lead author), Jianmin Gao and Lystranne Maynard; former graduate student David Saito; and Stephen R. Lynch, a science and engineering associate in the Department of Chemistry. The work was supported by the National Institutes of Health and by Stanford Graduate Fellowships.



#43 Lazarus Long

  • Topic Starter
  • Life Member, Guardian
  • 8,116 posts
  • 242
  • Location:Northern, Western Hemisphere of Earth, Usually of late, New York

Posted 03 November 2003 - 03:02 PM

More important discoveries from DeCode Genetics. Which BTW, has almost doubled in value since I put it on our watch list. For any of you that are making money on this congratulations.

This post should be linked over to Skeletal Issues as well.
http://imminst.org/f...f=117&t=1574&s=

Laz

http://www.nytimes.c.../03OSTE.html?hp
Posted Image
Icelandic Company Says It Has Found Osteoporosis Gene
By NICHOLAS WADE
Published: November 3, 2003

A gene linked to osteoporosis has been identified by Decode Genetics, the Icelandic company that is leading efforts to find the genes that underlie common human diseases.

People with any of three specific variants of the gene have a threefold risk of developing the disease, which is characterized by brittle bones.

A test for the variant forms of the gene is being developed by Roche Diagnostics and will be available in diagnostic laboratories at the beginning of next year, said Dr. Kari Stefansson, chief executive of Decode. The test need be taken only once in a lifetime, and if a gene variant were found, a high-calcium diet and plenty of exercise would be prescribed, Dr. Stefansson said.

Other genes have been linked to osteoporosis, but results vary from one population to the next. The new gene could be the first consistent contributor to the disease if its link, found so far in three populations, holds worldwide. The finding is being published today in the new online journal Public Library of Science.

Osteoporosis is an increasingly common disease as the population ages. It affects both sexes but particularly women after menopause. There are more than a million bone fractures a year in the United States from osteoporosis.

The new finding comes at a time of particular difficulty for doctors trying to treat the disease. Supplements of estrogen, a hormone that dwindles at menopause, prevent bone loss effectively, but a group of researchers recommended last month that estrogen not be prescribed solely to treat or prevent osteoporosis because of the slightly increased risk of breast cancer for those who take it. The Food and Drug Administration has not yet issued an opinion on the issue.

None of the available alternatives to estrogen is ideal, and the new gene found by Decode may help the search for better drugs.

The Decode team, led by Dr. Unnur Styrkarsdottir, scanned the genomes of 207 Icelandic families with at least one member who had both low bone-mineral density and bone fractures. Searching for stretches of DNA that the patients might have inherited in common, the Decode team identified a gene on Chromosome 20 called BMP-2, for bone morphogenetic protein-2.

The BMP-2 gene exists in several versions that differ very slightly in their sequence of DNA units. The Decode team found that three of these versions presented a particular risk for osteoporosis, since 30 percent of their patients had one or another of them. Carrying one of these versions does not guarantee that a person will develop osteoporosis, but it does make the risk three times as great, Dr. Stefansson said.

A major question is how far the Icelandic findings will prove true in other populations. Iceland was populated from the 10th century onward by vikings from Norway who had picked up several wives apiece from Ireland. Though disease genes found in Iceland are always relevant elsewhere, Dr. Stefansson said, the population tends to have fewer variants of each gene. To capture all such variants with a diagnostic test, the gene needs to be studied elsewhere.

Dr. Stefansson said the link between the BMP-2 variants and osteoporosis had been confirmed in a Danish population and was in the process of being validated in the United States in a group of women who have been studied for many years at the University of California at San Francisco.

Experts in bone loss tend to be skeptical of claims that specific genes are involved in osteoporosis, because several past claims have proved exaggerated.

"So this is one more of a long list," said Dr. Lawrence G. Raisz, chairman of the National Osteoporosis Foundation's scientific advisory board. "Not until much larger studies are done can we even guess. But it's exciting."

Apart from the statistical genetics that support the finding, the Decode result is intuitively plausible: the company conducted an impartial search of the whole human genome and alighted on a gene that was known independently to enhance bone formation.

"I love this stuff," said Dr. Gregory Mundy, an osteoporosis expert at the University of Texas Health Science Center, who has been studying drugs that stimulate the BMP-2 gene. "It supports what we have been doing for a number of years and gives it good credence."

An available measure for the weakening of the bones is called the bone mineral density test, or B.M.D. But the test has been criticized because everyone starts to lose bone strength after a certain youthful peak, and many people have a low score but do not get fractures. Bone density, it seems, does not fully reflect bone quality.

Dr. Stefansson said the test based on BMP-2 would be more useful because it was more predictive. Whereas the density test shows the state of a person's current mineral loss, which may or may not lead to fractures, a positive gene test, taken at any time in a person's life, would indicate a definite risk and would dictate that the patient follow a diet and exercise regimen to allay it, Dr. Stefansson said.

Finding the genes that underlie the common diseases was a central justification of the Human Genome Project, the multiyear effort to sequence the genome. By combining knowledge of the sequence with the special features of the Icelandic population, Decode Genetics has taken a substantial lead in tracking down the variant genes that cause such diseases.

So far the company has discovered 15 such genes, Dr. Stefansson said. Descriptions of four have now been published in scientific journals, and an additional 11 are awaiting publication.

#44 chubtoad

  • Life Member
  • 976 posts
  • 5
  • Location:Illinois

Posted 04 November 2003 - 12:48 AM

http://www.scienceda...31031062956.htm
Source: Arizona State University
Date: 2003-11-03


Researchers Build Microfluidic Devices Using Principles Of Electronic Integration



TEMPE, Arizona -- Advances in development of lab-on-chip devices, which shrink and potentially simplify laboratory tests like DNA analysis, have largely been tempered by the inherent complexity of the systems they are trying to replace. DNA analysis usually requires a laboratory full of instruments and several days to obtain results.


But now a team of researchers at Arizona State University report that they have made several advances in the area of microfluidic component design, fabrication and integration, bringing the technology to the point where DNA analysis could be done simply and in significantly less time than required today. The researchers are borrowing their ideas from what has become the king of small-scale integration – microelectronic integrated circuits (IC).

"We've basically taken some of the primary ideas of electronic integration and applied them to microfluidic devices. This new platform is called microfluidic IC," said Robin Liu, project manager at the Center for Applied Nano-Bioscience (ANBC) at the Arizona Bio Design Institute. "The novelty here is instead of having electrons flow between electronic chips, with microfluidics we have very tiny amounts of fluid moving between chips."

Liu and his colleagues detail their research findings in an article, "Development of integrated microfluidic system for genetic analysis." The article is the cover story of the October 2003 SPIE Journal of Microlithography, Microfabrication and Microsystems.

Liu said the advantages of integrated microfluidic devices include being able to build sophisticated devices from relatively simple parts, modularity of components, standardization of microfluidic chips and the ability to plug in and unplug specific parts of an overall system.

"Traditionally, every time you change the bioassay procedure in a microfluidic device, you have to redesign a whole chip," he explained. "This complicates everything, because then the fabrication process has to be changed, the integration has to be changed, the design has to be changed, everything has to be changed.

"Using an integrated circuit approach, we can exchange one of the components simply by unplugging it and plugging in a different one to achieve different functionalities of the overall system," Liu said. "It is a very flexible platform and any time you need to change the assay (a specific test) or you need to change the reactions, you just unplug the module and plug in a different module."

The article describes several approaches to the integration of complex functionalities in microfluidics. They include development of micromixers, microvalves, cell capture, micro polymerase chain reaction devices and new methods for making intricate, minute parts out of plastics.

But it is the integration, the bringing together of these disparate parts, to work in one overall, yet minute operating system, that is the most important advance, Liu said.

"From an integrations standpoint this simplifies assembly," he said. "Instead of putting every component onto a single device, one chip can be a microvalve, one chip can be a micropump. We actually build the overall system by assembling the pieces.

"Hopefully, this will be the standard procedure for microfluidics in the future," he added. "Just like the integrated circuit is the standard for microelectronics."

The end result would be a microfluidic device that can dramatically simplify some laboratory analysis procedures. For example, such a microfluidic device could be used to provide direct sample-to-answer analysis of DNA samples. That is, a lab technician would put a patient's blood in one end of the device and it would provide DNA data (in hours or minutes instead of days) showing if the patient has a certain disease, cancer or HIV.

Such a fully integrated device would require no external pressure sources, fluid storage, mechanical pumps, or valves that are necessary for fluid manipulation, eliminating possible sample contamination and simplifying device operation. This device provides a cost effective solution to direct sample-to-answer genetic analysis, and thus has potential impact in the fields of rapid disease diagnostics, environmental testing and biological warfare detection.


#45 kevin

  • Member, Guardian
  • 2,779 posts
  • 822

Posted 10 November 2003 - 01:25 AM

", ereg_replace("
", " ", "









Link: http://www.eurekaler...o-tsl110603.php
Date: 11-09-03
Author:
Michael C. Purdy -br-
purdym@msnotes.wustl.edu -br-
ph 314-286-0122
Source: Washington University School of Medicene
Title: Ten-year study leads researchers to psoriasis genes
")) ?>


Ten-year study leads researchers to psoriasis genes
Other genes, environmental factors also likely to contribute to prevalent skin disorder
St. Louis, Nov. 9, 2003 -- After a decade of searching, researchers have identified three genes linked to psoriasis, a potentially debilitating and disfiguring skin condition characterized by burning or itching patches of raised red skin.

The project's leader, Anne Bowcock, Ph.D., professor of genetics, of medicine and of pediatrics at Washington University School of Medicine in St. Louis, says the results could help scientists understand the molecular details of what happens in psoriasis and improve ways to treat the condition. The study will be published online by Nature Genetics on Nov. 9.

"Now we can look at the functional roles of these genes -- how they normally keep the skin and the immune system from damaging healthy tissue with their defensive mechanisms," Bowcock explains. "These results are going to help us find answers for some very important questions, including how changes in cellular mechanisms cause the disease and whether we can predict who is going to develop the disease early on."

Psoriasis is a complex trait -- a disorder linked to several genes and environmental factors. It comes in a variety of forms, including psoriatic arthritis, which causes additional arthritis-like symptoms. The condition can be severely disabling and afflicts up to 30 percent of all psoriasis patients.

The protagonist of The Singing Detective, a new movie currently in limited release in New York and Los Angeles, suffers from psoriatic arthritis. The film, which stars Robert Downey Jr. and Mel Gibson, is based on a play and television series by the late British author Dennis Potter, who suffered from the disease in real life.

According to the National Psoriasis Foundation, 4.5 million Americans have been diagnosed with the disorder and it afflicts about 2 percent of people in Western nations.

Scientists strongly suspect the immune system plays a major role in the disorders.

"We think the immune system may be overactive in some way that leads to damage to healthy tissue," Bowcock says. "Or the disease may be turning on a class of immune cells that can't be turned off properly. This could include immune cells in the skin."

Many psoriasis patients also have other disorders wholly or partially caused by immune system attacks on healthy tissue, including diabetes, lupus and Crohn's disease. A variety of environmental factors, including stress and infection by the streptococcus bacteria or HIV, are associated with the onset of psoriasis symptoms.

"HIV is becoming a serious trigger factor," Bowcock says. "In fact, psoriasis was very rare in Africa, but is now an additional complication in some of the HIV patients in Africa."

Bowcock is the director of the National Psoriasis Tissue Bank, which is located at the School of Medicine. To find the genes, she and her colleagues at Baylor University, the University of Washington in Seattle, Rockefeller University and the University of California in San Francisco analyzed DNA from 242 Northern European families with at least two affected individuals.

The search took a decade because they were looking for very subtle effects. The genes involved -- SLC9A3R1, NAT9 and RAPTOR -- didn't change much. Furthermore, researchers found that the forms of the genes that increased risk of psoriasis were present in about 37 percent of a group of people not suffering from the disease.

"Since only 2 percent of the general population develops psoriasis, there are clearly many other genes involved in determining psoriasis risk, and the genes we identified are low-risk," Bowcock says. "But it's encouraging because they're not genes we would have predicted to be involved in psoriasis, and now that we've found them the connections are starting to make sense."

Bowcock and her colleagues have found early evidence suggesting the genes may affect the development of immune system cells called T cells. Two of the genes, SLC9A3R1 and NAT9, under certain conditions, may be regulated by RUNX1, a gene involved in the development of blood cells including those of the immune system.

Bowcock notes that many of the new therapies for psoriasis are directed at reducing the activity of the immune system.

"It's therefore tantalizing that RUNX has been implicated in psoriasis, because RUNX is produced by cells of the immune system and thought to have a regulatory role in that system," Bowcock says. "In addition, the skin, like the immune system, has an important role in protecting us from infectious organisms. That role is poorly understood, as are the reasons why psoriasis affects the skin. This gene may help us begin to fill in some of those gaps."

Bowcock says she is intrigued by the possibility that the genes may be connected to other autoimmune diseases. The skin condition eczema, for example, has been linked to the same region of chromosome 17 where the three psoriasis genes were found.

"We're just putting together the first pieces of a big puzzle," Bowcock says. "If making progress in understanding psoriasis also leads us to new insights into other autoimmune diseases, that would be a double benefit."

In addition to probing the effects of these three genes and continuing the hunt for others, Bowcock and her colleagues want to see if they can use already identified genes to create a model of psoriasis in mice or other animals.


###
Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, Gordon D, Heffernan M, Wright Daw JA, Robarge J, Ott J, Kwok PY, Menter A, Bowcock AM. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with psoriasis susceptibility. Nature Genetics, early online edition Nov. 9, 2003.

Funding from the National Institutes of Health and the National Psoriasis Foundation.

The full-time and volunteer faculty of Washington University School of Medicine are the physicians and surgeons of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.
-------------------------


#46 Cyto

  • Guest
  • 1,096 posts
  • 1

Posted 18 December 2003 - 08:11 PM

SiBiono

The treatment consists of an adenovirus designed to insert a gene called p53. This gene codes for a protein that triggers cell suicide when cells start to run amok, preventing them becoming cancerous.

Many tumours arise after the mutation or inactivation of p53, and in cancers of this type restoring the protein should kill the tumour cells. This approach has already been tried in the US, with mixed results.

SiBiono decided to test the treatment on head and neck squamous cancers, as p53 is known to be mutated in over 60 per cent of these tumours. This form of cancer is also particularly common in China.

In the largest clinical trial, 120 patients with nasopharyngeal cancer were given either radiotherapy alone, or Gendicine and radiotherapy. The p53-carrying viruses were injected directly into tumours once a week for eight weeks, and most patients were monitored for more than a year afterwards.

In 64 per cent of patients given Gendicine there was complete regression of primary tumours, a rate three times as great as that in the radiotherapy-only group. Peng hopes the virus will work against other kinds of cancers too.

A dose will cost just 3000 yuan ($360), Peng told New Scientist, and can easily be administered by any doctor.


Krannert Institute of Cardiology

The primary substance for the gene therapy treatment is the human protein, fibronectin.

David Williams, another principal investigator and a member of the Herman B Wells Center for Pediatric Research at the IU Medical Center, said the protein has adhesive characteristics, which help transfer genes into cells that are used in this procedure.

"In essence, think of fibronectin as Velcro and retroviral particles and stem cells as balls. Envision that, like Velcro, the fibronectin allows attachment of the retroviral particles and stem cells, or balls, immediately adjacent to each other. This then permits genes to pass easily from the retroviral ball to the stem cell ball," Williams said in a statement.

"This is a gene product that stimulates the growth of blood vessels," Breall explained. "So, ultimately, preliminary studies have shown that people who do get this product feel better and are able to exercise longer."



#47 chubtoad

  • Life Member
  • 976 posts
  • 5
  • Location:Illinois

Posted 16 January 2004 - 01:12 AM

http://www.scienceda...40115075138.htm
Source: Stanford University Medical Center
Date: 2004-01-15

Gene-disabling Techniques Simplified By Stanford Team

STANFORD, Calif. - Sometimes the first step to learning a gene's role is to disable it and see what happens. Now researchers at the Stanford University School of Medicine have devised a new way of halting gene expression that is both fast and cheap enough to make the technique practical for widespread use. This work will accelerate efforts to find genes that are involved in cancer and the fate of stem cells, or to find genes that make good targets for therapeutic drugs.

The technique, published in the February issue of Nature Genetics and now available online, takes advantage of small molecules called short interfering RNA, or siRNA, which derail the process of translating genes into proteins. Until now, these molecular newcomers in genetics research have been difficult and expensive to produce. Additionally, they could impede the activity of known genes only, leaving a swath of genes in the genetic hinterlands unavailable for study.


"siRNA technology is incredibly useful but it has been limited by expense and labor. A better method for generating siRNA has been needed for the whole field to move forward," said study leader Helen Blau, PhD, the Donald E. and Delia B. Baxter Professor of Pharmacology. She said some companies are in the process of creating pools, or libraries, of siRNA molecules for all known genes in specific organisms but these libraries aren't yet available.

Pathology graduate students George Sen, Tom Wehrman and Jason Myers became interested in creating siRNA molecules as a way of screening for genes that alter the fate of stem cells - cells that are capable of self-renewal and the primary interest of Blau's lab. The students hoped to block protein production for each gene to find out which ones play a critical role in normal stem cell function.

"I told them that creating individual siRNAs to each gene was too expensive," said Blau. Undaunted, the students came up with a protocol for making an siRNA library to obstruct expression of all genes in a given cell - including genes that were previously uncharacterized. They could then pull individual molecules like books from a shelf to test each one for a biological effect.

The team had several hurdles to overcome in developing their protocol. The first was a size limit - an siRNA molecule longer than 29 subunits causes wide-ranging problems in the cell. The key to overcoming this barrier was a newly available enzyme that snips potential siRNA molecules into 21-subunit lengths. A further step copied these short snippets into a form that could be inserted into a DNA circle called a plasmid. When the researchers put a single plasmid into a cell, it began churning out the gene-blocking siRNA molecule.

The group tested their approach by creating a handful of siRNA molecules to genetically disable three known genes. In each case, their technique generated siRNA that effectively blocked the gene in question. Wehrman said this technique of creating siRNA molecule libraries could be widely used to find genes that, when disabled, cause cells to become cancerous or alter how the cells respond to different drugs. These genes could then become potential targets for drugs to treat disease.


A paper in the same issue of Nature Genetics described a similar way of creating siRNA libraries. "Having two unrelated groups working on the same problem shows there has been a real need for the technology," Blau said. The Stanford group has filed a patent for its technique

#48 Aegist

  • Guest Shane
  • 1,416 posts
  • 0
  • Location:Sydney, Australia

Posted 18 January 2004 - 10:41 AM

The most interesting version of gene therapy that I have heard mentioned, is the idea of introducing an entirely new chromosome. This way we needn't worry about interfering with vital genes. Anyone know of any work done on that?

#49 manofsan

  • Guest
  • 1,223 posts
  • 56

Posted 20 January 2004 - 10:25 PM

Gene therapy approaches seem to be based on recombinant DNA -- ie. the idea of inserting/integrating/recombining new genes into the existing DNA material inside the cell. But is there any possibility of wholesale replacement of the entire existing chromosome set already in the cell?

The reason why I ask this, is because perhaps one day we will be able to design an entire genome from scratch, on our computer screens. Perhaps some kind macro-molecular synthesis machines/techniques will then enable us to render this idealized genome in chromosomal format.
Rather than trying to insert this genome bit by bit into existing cellular DNA, it would be preferable to just insert the whole pre-fabricated genome into the cells, supplanting the pre-existing genetic material.

But how could this be done? This approach would be in contrast to DNA recombinance. Is there any precedent in nature that would justify such an approach, or is this impossible fantasy?

One problem with DNA recombinance, is the danger of accidentally inserting into the middle of other genes so as to disrupt them, trigger them(oncogenes), or cause some undesirable reaction with existing genetic material.

Are there new techniques/methods for DNA recombinance which are addressing the aforementioned shortcomings of the recombinant approach?

#50 manofsan

  • Guest
  • 1,223 posts
  • 56

Posted 21 January 2004 - 01:51 AM

The most interesting version of gene therapy that I have heard mentioned, is the idea of introducing an entirely new chromosome. This way we needn't worry about interfering with vital genes. Anyone know of any work done on that?


Hi, your posting interests me tremendously, regarding introduction of whole chromosomes. Do you have any links for me to read up on?
When you say introducing an entirely new chromosome, does this also take care of eliminating the pre-existing counterpart chromosome? Or do you end up with extra chromosomes in the end?

Getting rid of the pre-existing DNA sounds a bit of a messy problem, unfortunately. Perhaps if your new replacement chromosomes had a modified telomere, while your pre-existing chromosomes could be unravelled thru some enzyme that attacked their unmodified telomeres -- that might be a way to do it. But could this be done reliably/consistently across billions of cells of an adult organism?

#51 treonsverdery

  • Guest
  • 1,312 posts
  • 161
  • Location:where I am at

Posted 21 January 2004 - 08:02 AM

Think on fluorouracil or things like A C G T that will make AT or GC links that are just a little different than ordinary ACGT

It might be a little like a compiler

#52 manofsan

  • Guest
  • 1,223 posts
  • 56

Posted 24 February 2004 - 11:59 PM

http://www.scienceda...40224104745.htm

Study May Improve Gene Therapy Safety
CHAPEL HILL -- New research from the University of North Carolina at Chapel Hill may hold keys to improving the safety of human gene therapy.

The study showed that the messenger can be as important as the message: Viruses genetically engineered for use as delivery vehicles for transferring therapeutic genes into the body may alone influence gene expression, or which genes are turned on. Moreover, depending on the type of virus, they may do so in potentially harmful ways.

"This basically tells us that the messenger plays an important role in gene expression," said study co-author Dr. Richard J. Samulski, professor of pharmacology and director of UNC's Gene Therapy Center. "At the molecular level, a cascade of cell signaling events occurs irrespective of the therapeutic gene. This is something we didn't anticipate." The report will appear in the March issue of Molecular Therapy, the American Society of Gene Therapy's journal.

The study focused on two viruses: adenovirus and adeno-associated virus, or AAV. These viruses, when genetically engineered, have shown particular promise in laboratory studies as gene transfer vectors and have been used in more than 170 clinical trials.

Samulski and UNC co-author Dr. Jackie L. Stilwell, a postdoctoral researcher, reported there has been significant progress in understanding how viral gene therapy vectors behave in laboratory animals, in terms of acute toxicity effects.

However, they wrote, "systematic comparison of their effects upon cells at the molecular level has not been established." In that regard, the new research offers important new and potentially useful information for predicting the safety of gene delivery in people.

"The field has advanced so rapidly that we can now do toxicity profiles inside an individual cell," Samulski said. "And basically what we're doing here is asking what happens to the genome if a vector or virus comes into the cell."

In their experiments on cultured lung cells, Samulski and Stilwell used DNA microarray technology to examine gene expression. This technology can monitor the whole genome on a single silicon chip, giving researchers a better picture of the interactions among thousands of genes simultaneously by displaying patterns of gene expression.

Exposure to AAV either as an intact virus or as a recombinant vector shell affected gene expression minimally and in patterns not associated with potential harm to the host organism, the report said. In addition, exposure to the empty capsid of AAV - the protein coat of the virus devoid of DNA - also produced minimal response from the genes. For example, only 1.9 percent of genes showed changes in expression in cells infected by recombinant AAV.

In contrast, gene expression after exposure to intact adenovirus and recombinant adenovirus vector was much broader and included the activation of immune and stress response genes. Lung cells exposed to empty adenovirus capsid showed a decrease in changes in cellular gene expression, although some were related to stress response genes.

This study provides a systematic explanation for the relative safety profiles of two commonly used gene therapy vector classes, Samulski said.

"The take-home message here is we can now monitor the genes that get turned on when you put a vector on the cell," he said. "We can then make changes to the vectors and observe how their safety profiles improve prior to their use clinically."

"As we make architectural changes to the delivery system, we can see the cell's response to it," Stilwell added. "The study represents the start of a useful database of gene expression signatures for people involved in vector development."

The next step for the UNC researchers is to continue exploring the vector-associated gene expression signatures in other cell types and to extend the work to whole animals.

"I think everybody involved in designing vectors will continue to build on this database," Samulski said. "We're laying the foundation here for that to happen."

Samulski, a pioneer in AAV research, said the new study further confirms his choice to study and develop altered AAV for gene therapy. Along with its potential for fewer toxic effects than that of many other viruses studied for use in gene therapy, a gene delivered via AAV remains active in cells for months or even years, he added.

Last year, a form of gene therapy created and developed in Samulski's laboratory and based on AAV was approved by the U.S. Food and Drug Administration and given to children with Canavan disease, a rare, inherited neurological disorder. It marked the first FDA approval for clinical use of an AAV vector for gene therapy that was produced by a U.S. academic institution.


The new research was supported by grants from the National Institutes of Health and the Cystic Fibrosis Foundation.

#53 manofsan

  • Guest
  • 1,223 posts
  • 56

Posted 29 February 2004 - 08:51 PM

Here's an interesting article:

http://www.seedquest...bruary/7887.htm

This stuff is for plants, but could also have applications for humans and animals. I still wish there was a way to swap chromosomes. If a reliable, effective way to do this were ever developed, then gene therapy could really take off.

#54 ddhewitt

  • Guest
  • 168 posts
  • 0
  • Location:New England

Posted 22 March 2004 - 12:52 AM

Site specific recombination events can be done to a certain extent in mice.

This is how knock out mice are produced like the winner of the Methuselah Mouse Prize. Sequences can be inserted as well as deleted by these techniques. The manipulations are done on cells in culture which are then used to generate the altered mouse.

Duane

#55 Cyto

  • Guest
  • 1,096 posts
  • 1

Posted 05 April 2004 - 06:58 PM

Genetic Trick Adapted from Viruses Makes Gene Therapy Vectors More Versatile

A genetic trick used by viruses to replicate themselves has been adapted for laboratory use to build complex protein structures required by immune system cells, according to investigators at St. Jude Children's Research Hospital.  This approach could also be used to develop new gene therapy vectors in cases when cells must be modified to make high levels of different proteins. A vector is a DNA molecule used to ferry specific genes into cells in order to give those cells the ability to make particular proteins.  A report on this work appears in the May 2004 issue of Nature Biotechnology.

What they did
The technique is based on a genetic trick, called a self-cleaving 2A peptide, which is used by some viruses to produce multiple proteins from a single length of DNA; i.e., a single, long protein is produced that automatically breaks into multiple, distinct proteins.

St. Jude researchers used genetically modified mouse immune system cells called T lymphocytes to test the efficiency of this technique in making the CD3 complex, which is part of the T cell receptor, a large protein lodged in the cell's membrane. The receptor allows T cells to "sense" targets that the cells are programmed to destroy. Without the CD3 complex, the T cell receptor is incomplete and cannot perform its immune function.

The St. Jude researchers used retroviral vectors as the delivery system into which they inserted cassettes (groups of genes) that contained genes for the four CD3 proteins, separated by the 2A peptides. These 2A peptides acted like cleavers to break apart the long protein into the four different, smaller CD3 proteins. The cell used these smaller proteins to build the large TCR:CD3 receptor. In order to replicate inside a cells, the retrovirus RNA must first be changed back into DNA. A retrovirus is a virus whose genetic material is RNA instead of DNA.

The St. Jude team used these multicistronic retroviral vectors (vectors carrying several different genes) to deliver the 2A peptide-linked CD3 gene cassettes into hematopoietic stem cells from mice that lacked the CD3 proteins, and thus could not make T cells. These genetically modified stem cells subsequently developed and restored T cell development in the mice. Hematopoietic stem cells are "parent" cells that give rise to all the red and white cells found in blood.



#56 John Schloendorn

  • Guest, Advisor, Guardian
  • 2,542 posts
  • 157
  • Location:Mountain View, CA

Posted 05 April 2004 - 09:12 PM

Another God, you might want to look into this or this.

#57 Cyto

  • Guest
  • 1,096 posts
  • 1

Posted 06 April 2004 - 04:02 AM

Leading experts in field of gene therapy to meet in Minneapolis

The latest research in the field of gene therapy will be showcased at the 7 th Annual Meeting of the American Society of Gene Therapy (ASGT) in Minneapolis , June 2-6, 2004. New developments on the use of gene therapy for treating infections diseases such as cancer and AIDS, cardiovascular diseases, and cystic fibrosis will be explored in a variety of educational workshops and symposia.

Program topics will also feature:

* Innovative approaches of gene therapy
* Long term follow up of gene therapy clinical trials
* International harmonization of regulatory standards for clinical trials

#58 kevin

  • Member, Guardian
  • 2,779 posts
  • 822

Posted 16 April 2004 - 04:04 AM

Link: http://www.medicalne...php?newsid=7309


Longevity gene may also predict better outcome for breast cancer patients
16 Apr 2004

A gene known to promote longevity in animals has now been discovered to encode a tumor suppressor - a protein that helps prevent cancer, according to a study by a team of scientists from The University of Texas M. D. Anderson Cancer Center. The new gene, which was inactivated in two-thirds of patients studied, presents a potent new target for breast cancer therapy, the researchers say.

In a study published in the April 16, 2004, issue of the journal Cell, scientists describe how the presence of the protein, named Forkhead box class O3 (FOXO3), is associated with better outcomes for breast cancer patients. Conversely, if FOXO3 was inactivated, patients had worse outcomes.

"This is a very good prognostic marker for breast cancer patient outcome," said Mien-Chie Hung, Ph.D., the co-principal investigator of the study. "In addition, these proteins provide new targets for cancer therapy and prevention."

The research team, which was a collaboration between the laboratories of Mickey C.-T. Hu, Ph.D., and Hung, both of the Department of Molecular and Cellular Oncology at M. D. Anderson, demonstrated that FOXO3 is inactivated in many cancer patients by an enzyme called IKK and determined that IKK is an oncoprotein, a protein that can induce cancer.

"We have uncovered two important events and put them together in one story," says Hung. "This research has identified an important new tumor suppressor protein and a new oncogene that provide targets for cancer therapy. Previously, these proteins had been suspected to be involved in cancer, but there was no direct evidence for that."

The IKK oncoprotein belongs to a family of enzymes called kinases. Researchers have shown that blocking certain kinases can be an effective way to block cancer. New generation cancer drugs such as Gleevec, which has been effective in treating leukemia patients, work by zeroing in and inactivating a kinase molecule. Such targeted therapies are designed to kill cancer cells while avoiding serious damage to other, non-cancerous cells.

The scientists discovered the protein's role in cancer while studying how normal cells can turn cancerous. They showed that IKK can attach to the FOXO3 protein and inactivate it. When the normal function of FOXO3 is blocked, the cell can multiply unchecked.

Once they had established that inactivated FOXO3 protein could lead to cancer, the researchers examined its role in tumor cells from 131 breast cancer patients. They found FOXO3 in 113 out of 131 samples. Of the 113 samples with FOXO3, the protein was inactive in 83 and active in 30 samples.

When they looked at patient survival, they found a strong correlation between active FOXO3 and better patient survival. Additional research revealed the FOXO3 protein can be found in patients with stomach, liver and lung cancer. However, the scientists did not study enough of these patient samples to say how important the gene is in these cancers.

In additional laboratory studies, the scientists demonstrated that a slightly altered form of FOXO3 that can't be inactivated by IKK acts as an even more potent tumor suppressor than the normal FOXO protein.

"This mutant FOXO3 may be an even more powerful tumor suppressor than the normal FOXO3 protein," says Hung. "This finding may provide a new avenue for cancer gene therapy or other targeted cancer therapies."

The presence of active Forkhead (FOXO) protein has been linked to longevity in laboratory animals such as the nematode worm, says Hung. Hu and Hung's discovery that FOXO3 is a tumor suppressor may provide a clue to the gene's ability to increase lifespan in animals. But exactly how a tumor suppressor could increase lifespan remains a mystery.

"That is the million-dollar question," Hung says.

The research was supported by grants from the National Institutes of Health, the M. D. Anderson Breast Cancer Research Program, the Susan G. Komen Breast Cancer Foundation, and a Cancer Center Supporting Grant. All authors of the study, who included Dung-Fang Lee, Weiya Xia, M.D., Jer-Yen Yang, Yiyu Zou, Ph.D., Shilai Bao, Ph.D., and Ryuji Kobayashi, Ph.D., are of the M. D. Anderson Cancer Center.

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center

#59 Cyto

  • Guest
  • 1,096 posts
  • 1

Posted 03 May 2004 - 11:24 PM

Chromatin remodeling

In a finding that deepens our understanding of epigenetic regulation, researchers at the Gregor Mendel Institute of Molecular Plant Biology in Vienna have identified a novel protein in Arabidopsis that may help so-called short guide RNAs and silencing effector proteins target specific DNA sequences for modification.

The 'nuclear side' of RNA interference (RNAi) is increasingly recognized as an important part of RNA-mediated gene silencing pathways. Short RNAs and proteins of the RNAi machinery can direct epigenetic modifications, such as DNA cytosine methylation and histone methylation, to homologous regions of the genome in various organisms. Still unclear is whether short RNAs interact directly with target DNA sequences by base pairing and if so, how they gain access to target DNA that is packaged into nucleosomes in chromatin.

In a genetic a screen for mutants defective in RNA-directed DNA methylation in Arabidopsis thaliana, Dr. Tatsuo Kanno and colleagues identified DRD1, a previously undefined SNF2 chromatin remodeling protein in plants. The involvement of DRD1 in RNA-directed DNA methylation suggests that chromatin remodeling is required to render nucleosomal DNA accessible to RNA signals and/or DNA methyltransferases. DRD1 is the first chromatin remodeling factor implicated in an RNA-guided epigenetic modification of the genome.



Click HERE to rent this GENETICS advertising spot to support LongeCity (this will replace the google ad above).

#60 manofsan

  • Guest
  • 1,223 posts
  • 56

Posted 04 May 2004 - 12:08 AM

So is RNA the main mediator of this epigenetic methylation stuff? If not, then what is? Because methylation seems damn important for turning the genetic switches on and off. It's like we're suddenly learning about this whole secondary arena where the major transactions of senescence and development take place.

Are there any other epigenetic factors other than methyl groups? Or is methylation the only epigenetic game in town?




0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users